Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Short-term Investments (2022 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Short-term Investments for 4 consecutive years, with $22.8 million as the latest value for Q4 2025.

  • Quarterly Short-term Investments rose 61.0% to $22.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $22.8 million through Dec 2025, up 61.0% year-over-year, with the annual reading at $22.8 million for FY2025, 61.0% up from the prior year.
  • Short-term Investments hit $22.8 million in Q4 2025 for Harmony Biosciences Holdings, down from $25.6 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $79.3 million in Q4 2022 to a low of $14.2 million in Q4 2024.
  • Historically, Short-term Investments has averaged $35.5 million across 4 years, with a median of $29.6 million in 2024.
  • Biggest five-year swings in Short-term Investments: soared 203.71% in 2023 and later tumbled 66.06% in 2024.
  • Year by year, Short-term Investments stood at $79.3 million in 2022, then tumbled by 47.31% to $41.8 million in 2023, then crashed by 66.06% to $14.2 million in 2024, then soared by 61.0% to $22.8 million in 2025.
  • Business Quant data shows Short-term Investments for HRMY at $22.8 million in Q4 2025, $25.6 million in Q3 2025, and $19.2 million in Q2 2025.